211 related articles for article (PubMed ID: 35853277)
21. Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
Asanuma K; Ishihara M; Nakamura T; Uchida K; Hagi T; Kageyama S; Shiku H; Sudo A
Anticancer Res; 2023 Dec; 43(12):5737-5748. PubMed ID: 38030212
[TBL] [Abstract][Full Text] [Related]
22. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
[TBL] [Abstract][Full Text] [Related]
23. A novel murine T-cell receptor targeting NY-ESO-1.
Rosati SF; Parkhurst MR; Hong Y; Zheng Z; Feldman SA; Rao M; Abate-Daga D; Beard RE; Xu H; Black MA; Robbins PF; Schrump DA; Rosenberg SA; Morgan RA
J Immunother; 2014 Apr; 37(3):135-46. PubMed ID: 24598449
[TBL] [Abstract][Full Text] [Related]
24. Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.
Gong W; Hoffmann JM; Stock S; Wang L; Liu Y; Schubert ML; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Shiku H; Schmitt M; Sellner L
Cancer Immunol Immunother; 2019 Jul; 68(7):1195-1209. PubMed ID: 31177329
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.
Xia Y; Tian X; Wang J; Qiao D; Liu X; Xiao L; Liang W; Ban D; Chu J; Yu J; Wang R; Tian G; Wang M
Oncol Lett; 2018 Dec; 16(6):6998-7007. PubMed ID: 30546433
[TBL] [Abstract][Full Text] [Related]
26. Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.
Qiu CX; Bai XF; Shen Y; Zhou Z; Pan LQ; Xu YC; Zhao WB; Chen SQ
Bioconjug Chem; 2020 Dec; 31(12):2767-2778. PubMed ID: 33237767
[TBL] [Abstract][Full Text] [Related]
27. NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route.
Amissah OB; Chen W; de Dieu Habimana J; Sun Y; Lin L; Liu Y; Wang L; Liu Z; Mukama O; Basnet R; Liu H; Li J; Ding X; Lv L; Chen M; Liang Y; Huang R; Li Z
Cancer Cell Int; 2024 Feb; 24(1):64. PubMed ID: 38336680
[TBL] [Abstract][Full Text] [Related]
28. TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan AR; Chaipan C; Winkelbach K; Wimberger S; Jeong JS; Joshi B; Stein RB; Underwood D; Castle JC; van Dijk M; Seibert V
Front Immunol; 2019; 10():2501. PubMed ID: 31695703
[TBL] [Abstract][Full Text] [Related]
29. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
30. Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.
Itoh M; Kawagoe S; Nakagawa H; Asahina A; Okano HJ
Exp Dermatol; 2023 Feb; 32(2):126-134. PubMed ID: 36222007
[TBL] [Abstract][Full Text] [Related]
31. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.
Mastaglio S; Genovese P; Magnani Z; Ruggiero E; Landoni E; Camisa B; Schiroli G; Provasi E; Lombardo A; Reik A; Cieri N; Rocchi M; Oliveira G; Escobar G; Casucci M; Gentner B; Spinelli A; Mondino A; Bondanza A; Vago L; Ponzoni M; Ciceri F; Holmes MC; Naldini L; Bonini C
Blood; 2017 Aug; 130(5):606-618. PubMed ID: 28637663
[TBL] [Abstract][Full Text] [Related]
32. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
[TBL] [Abstract][Full Text] [Related]
33. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.
Nowicki TS; Berent-Maoz B; Cheung-Lau G; Huang RR; Wang X; Tsoi J; Kaplan-Lefko P; Cabrera P; Tran J; Pang J; Macabali M; Garcilazo IP; Carretero IB; Kalbasi A; Cochran AJ; Grasso CS; Hu-Lieskovan S; Chmielowski B; Comin-Anduix B; Singh A; Ribas A
Clin Cancer Res; 2019 Apr; 25(7):2096-2108. PubMed ID: 30573690
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1
D'Angelo SP; Melchiori L; Merchant MS; Bernstein D; Glod J; Kaplan R; Grupp S; Tap WD; Chagin K; Binder GK; Basu S; Lowther DE; Wang R; Bath N; Tipping A; Betts G; Ramachandran I; Navenot JM; Zhang H; Wells DK; Van Winkle E; Kari G; Trivedi T; Holdich T; Pandite L; Amado R; Mackall CL
Cancer Discov; 2018 Aug; 8(8):944-957. PubMed ID: 29891538
[TBL] [Abstract][Full Text] [Related]
35. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
Frankiw L; Singh A; Peters C; Comin-Anduix B; Berent-Maoz B; Macabali M; Shammaie K; Quiros C; Kaplan-Lefko P; Baselga Carretero I; Ribas A; Nowicki TS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37156551
[TBL] [Abstract][Full Text] [Related]
37. CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA; Fraietta JA; Davis MM; Cohen AD; Weber KL; Lancaster E; Mangan PA; Kulikovskaya I; Gupta M; Chen F; Tian L; Gonzalez VE; Xu J; Jung IY; Melenhorst JJ; Plesa G; Shea J; Matlawski T; Cervini A; Gaymon AL; Desjardins S; Lamontagne A; Salas-Mckee J; Fesnak A; Siegel DL; Levine BL; Jadlowsky JK; Young RM; Chew A; Hwang WT; Hexner EO; Carreno BM; Nobles CL; Bushman FD; Parker KR; Qi Y; Satpathy AT; Chang HY; Zhao Y; Lacey SF; June CH
Science; 2020 Feb; 367(6481):. PubMed ID: 32029687
[TBL] [Abstract][Full Text] [Related]
38. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
Zhao Y; Zheng Z; Khong HT; Rosenberg SA; Morgan RA
J Immunother; 2006; 29(4):398-406. PubMed ID: 16799335
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.
Pan Q; Weng D; Liu J; Han Z; Ou Y; Xu B; Peng R; Que Y; Wen X; Yang J; Zhong S; Zeng L; Chen A; Gong H; Lin Y; Chen J; Ma K; Lau JYN; Li Y; Fan Z; Zhang X
Cell Rep Med; 2023 Aug; 4(8):101133. PubMed ID: 37586317
[TBL] [Abstract][Full Text] [Related]
40. Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Wang H; Xia Y; Yu J; Guan H; Wu Z; Ban D; Wang M
HLA; 2019 Jul; 94(1):39-48. PubMed ID: 30953385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]